Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

The Incidence Of Prostate Cancer Progression With Undetectable Serum Prostate Specific Antigen In A Series Of 394 Radical Prostatectomies.

M. Oefelein, N. Smith, M. Carter, D. Dalton, A. Schaeffer
Published 1995 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
PURPOSE Serum prostate specific antigen (PSA) has been reported to be a sensitive indicator of recurrent carcinoma after radical prostatectomy but it is not absolute. Disease progression with undetectable PSA levels has been described but the incidence of this phenomenon is unknown. MATERIALS AND METHODS We retrospectively analyzed the records of 394 consecutive men who underwent radical prostatectomy between 1980 and 1991 to characterize the incidence of recurrent carcinoma despite undetectable serum PSA levels. RESULTS Of the 394 men 133 had documented evidence of disease recurrence, 3 (2.3%) despite undetectable serum PSA levels (2 had local and systemic evidence of disease progression). Histological dedifferentiation characterized these recurrences. CONCLUSIONS Although a post-prostatectomy detectable serum PSA level precedes clinical evidence of disease progression by years, rare patients (2.3% in our series) in whom recurrent disease is characterized by marked histological dedifferentiation will remain negative for PSA.
This paper references
10.1056/NEJM199101243240406
Carcinoma of the prostate.
R. Gittes (1991)
10.1016/S0022-5347(17)40079-6
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
A. Partin (1990)
10.1016/S0022-5347(17)35302-8
Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer.
M. Aihara (1994)
10.1016/S0022-5347(17)41037-8
The value of serum prostate specific antigen determinations before and after radical prostatectomy.
P. Lange (1989)
10.1016/0090-4295(87)90318-9
Adult and Pediatric Urology
J. Gillenwater (1996)
10.1056/NEJM198710083171501
Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate
T. Stamey (1987)
10.1016/S0022-5347(17)38491-4
Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
J. Oesterling (1991)
10.1016/S0022-5347(17)35486-1
The enhanced detection of persistent disease after prostatectomy with a new prostate specific antigen immunoassay.
T. Takayama (1993)
10.1016/S0022-5347(17)39797-5
In situ hybridization of prostate-specific antigen mRNA in human prostate.
S. Qiu (1990)
10.1016/S0022-5347(17)39623-4
Prostate specific antigen and local recurrence after radical prostatectomy.
D. Lightner (1990)
Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy.
Ferguson Jk (1994)
10.1016/S0022-5347(17)38972-3
Clinical use of prostate specific antigen in patients with prostate cancer.
M. Hudson (1989)
Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.
A. Partin (1993)
10.1016/S0022-5347(17)36963-X
Recurrent prostate cancer despite undetectable prostate specific antigen.
T. Takayama (1992)
Follow-up after radical prostatectomy or radiation therapy for prostate cancer.
J. Montie (1994)
Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
J. Hsieh (1993)
10.1016/S0022-5347(17)38998-X
Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy.
D. E. Goldrath (1989)
10.1016/S0022-5347(17)41175-X
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
T. Stamey (1989)



This paper is referenced by
10.1109/TMI.2006.880667
Prostate mechanical imaging: 3-D image composition and feature calculations
V. Egorov (2006)
10.2995/JACSURG.31.648
Isolated solitary lung metastasis 12 years after radical prostatectomy for prostate cancer without elevation of the serum prostate-specific antigen level
Yoshihito Iijima (2017)
10.1055/a-1032-8126
Verumontanum-Mukosahyperplasie als Differenzialdiagnose eines Lokalrezidivs nach radikaler Prostatektomie
K. Drosos (2019)
10.1016/S0090-4295(99)80321-5
Assessment of endpoints for clinical trials for localized prostate cancer.
P. Schellhammer (1997)
Estudio de la osteoporosis inducida por la deprivación androgénica en pacientes con cáncer de próstata
A. Junquera (2008)
A guideline to clinical utility of prostate specific antigen.
W. Farhat (2000)
10.1016/J.CANRAD.2015.05.016
Suivi après radiothérapie des cancers de prostate : évaluation et prise en charge de la toxicité et de la récidive
G. Dupic (2015)
Salvage surgery for locally recurrent prostate cancer after radiation therapy
M. Tefilli (1998)
10.1002/PROS.20334
N‐cadherin switching occurs in high Gleason grade prostate cancer
M. Jaggi (2006)
10.1111/j.1464-410X.2004.04927.x
Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?
P. Gomez (2004)
10.3892/OL.2015.3940
Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.
C. Wang (2016)
anagement of Prostate Cancer: Global Strategies
ntonio Alcaraz (2006)
10.1016/S0022-5347(01)63239-7
(111) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY
D. Kahn (1998)
The Study of Biochemical and Clinical Failure after Radical Prostatectomy or Radiation Therapy in Localized Prostate Cancer
Kyu Il Ahn (2004)
10.1186/s12885-020-06827-z
Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level < 4 ng/ml: a population-based study
Zhibo Zheng (2020)
10.4172/2155-6156.1000500
Diagnostic Value of Serum Ghrelin Levels in Diabetic Men with Benign Prostate Hypertrophy
M. Wrzosek (2015)
10.1016/S0094-0143(05)70386-4
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
C. Pound (1997)
10.3332/ecancer.2014.435
Focal therapy in prostate cancer: the current situation
FX Jácome-Pita (2014)
10.1002/9781118347379.CH11
Posttherapy Follow‐up and First Intervention
Ernesto R. Cordeiro (2014)
10.1007/978-3-319-42623-5_75
Management of Nonmetastatic Failure Following Local Prostate Cancer Therapy
D. Ambuehl (2019)
10.1016/S0022-5347(01)61935-9
Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology.
M. Ohori (1999)
10.1016/S0094-0143(05)70344-X
Serum prostate-specific antigen elevation in the post-radical prostatectomy patient.
S. Malkowicz (1996)
10.1016/J.JURO.2007.03.010
Is routine digital rectal examination required for the followup of prostate cancer?
K. Warren (2007)
10.1016/S0302-2838(03)00046-0
Digital rectal exam following prostatectomy: is it still necessary with the use of PSA?
J. Lattouf (2003)
10.5603/NJO.2014.0070
Badania kontrolne po leczeniu w najczęstszych nowotworach litych
J. Jassem (2014)
10.1201/B14401-2
Anatomic Radical Prostatectomy in the Management of Localized Prostate Cancer
D. Lin (2004)
10.1016/S0022-5347(01)64243-5
Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate.
M. Oefelein (1997)
10.1016/S0090-4295(97)00090-3
Comparison of four automated prostate-specific antigen assays for detection of recurrence after radical prostatectomy.
H. Sanders (1997)
Tumornachsorge beim Prostatakarzinom: Die EAU-Guidelines als Grundlage für eine sinnvolle onkologische Nachsorge
A. S. Brandt (2008)
10.1097/00000421-199808000-00001
Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literature.
A. Safa (1998)
10.3322/caac.20026
Screening for Prostate Cancer
O. Brawley (2009)
10.1089/10915360152745849
Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study.
A. Tewari (2001)
See more
Semantic Scholar Logo Some data provided by SemanticScholar